Listen in the Podli app 🎧
Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:
- Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)
- Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)
- Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)
- Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)
- Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)
- Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)
- Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)
- Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03)
CME information and select publications
